Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01271933 · ClinicalTrials.gov registry record · Phase 3
Study Of A Controlled Release Formulation Of Pregabalin In Fibromyalgia Patients
A Phase 3 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 3
- Development phase
- 441
- Enrollment target
NCT01271933 is a Phase 3 study that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 441 participants.
The verdict
NCT01271933, a Phase 3 study, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 441 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of a controlled release formulation of pregabalin administered once daily as compared to placebo in the treatment of fibromyalgia. All patients will receive pregabalin; half of the patients will receive placebo at some point in the study.
Interventions
- DRUG placebo
- DRUG pregabalin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 441 participants |
| Start Date | 2011-03 |
| Est. Completion | 2012-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01271933
The ClinicalTrials.gov registry entry for NCT01271933 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 441 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01271933 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01271933 about?
NCT01271933 is a clinical study titled "Study Of A Controlled Release Formulation Of Pregabalin In Fibromyalgia Patients". The purpose of this study is to evaluate the efficacy and safety of a controlled release formulation of pregabalin administered once daily as compared to placebo in the treatment of fibromyalgia. All patients will receive pregabalin; half of the patients will receive placebo at some point in the stu...
What is the current status of trial NCT01271933?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 441 participants. The study started on 2011-03. Estimated completion is 2012-07.
What interventions are being tested in trial NCT01271933?
The interventions under investigation include: placebo (DRUG), pregabalin (DRUG).
Who is sponsoring clinical trial NCT01271933?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.